(S (NP (NP (JJ Malignant) (JJ Pleural) (NN Mesothelioma) (PRN (-LRB- -LRB-) (NP (NNP MPM)) (-RRB- -RRB-))) (CC or) (NP (JJ malignant) (NN mesothelioma) (PRN (-LRB- -LRB-) (NP (NNP MM)) (-RRB- -RRB-)))) (VP (VBZ is) (NP (NP (DT an) (JJ atypical) (, ,) (JJ aggressive) (NN tumor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ matures) (PP (IN into) (NP (NP (NN cancer)) (PP (IN in) (NP (NP (DT the) (NN pleura)) (, ,) (NP (NP (DT a) (NN stratum)) (PP (IN of) (NP (NN tissue)))))))) (S (VP (VBG bordering) (NP (DT the) (NNS lungs))))))))) (. .))
(S (S (NP (NP (NN Diagnosis)) (PP (IN of) (NP (NNP MPM)))) (VP (VBZ is) (ADJP (JJ difficult)))) (CC and) (S (NP (PRP it)) (VP (VBZ accounts) (SBAR (IN for) (S (NP (NP (QP (RB about) (CD seventy) (HYPH -) (CD five)) (NN percent)) (PP (IN of) (NP (DT all) (NN mesothelioma)))) (VP (VBD diagnosed) (ADVP (RB yearly)) (PP (IN in) (NP (NP (DT the) (NNP United) (NNP States)) (PP (IN of) (NP (NNP America)))))))))) (. .))
(S (S (VP (VBG Being) (NP (DT a) (JJ fatal) (NN disease)))) (, ,) (NP (NP (JJ early) (NN identification)) (PP (IN of) (NP (NNP MPM)))) (VP (VBZ is) (ADJP (JJ crucial) (PP (IN for) (NP (JJ patient) (NN survival))))) (. .))
(S (NP (PRP$ Our) (NN study)) (VP (VP (NP (NNS implements)) (S (NP (JJ logistic) (NN regression)))) (CC and) (VP (VBZ develops) (NP (NN association) (NNS rules)) (S (VP (TO to) (VP (VB identify) (NP (NP (JJ early) (NN stage) (NNS symptoms)) (PP (IN of) (NP (NNP MM))))))))) (. .))
(S (NP (PRP We)) (VP (VP (VBD retrieved) (NP (NP (JJ medical) (NNS reports)) (VP (VBN generated) (PP (IN by) (NP (NNP Dicle) (NNP University)))))) (CC and) (VP (VBD implemented) (NP (JJ logistic) (NN regression)) (S (VP (TO to) (VP (VB measure) (NP (DT the) (NN model) (NN accuracy))))))) (. .))
(S (NP (PRP We)) (VP (VBD conducted) (NP (NP (-LRB- -LRB-) (DT a) (-RRB- -RRB-) (JJ logistic) (NN correlation)) (, ,) (NP (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-)) (NP (NNP Omnibus) (NN test))) (CC and) (NP (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-)) (NP (NML (NNP Hosmer) (CC and) (NNP Lemeshow)) (NN test)) (PP (IN for) (NP (NN model) (NN evaluation)))))) (. .))
(S (ADVP (RB Moreover)) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD developed) (NP (NN association) (NNS rules)) (PP (IN by) (NP (NP (NN confidence)) (, ,) (NP (NN rule) (NN support)) (, ,) (NP (NN lift)) (, ,) (NP (NN condition) (NN support)) (CC and) (NP (NN deployability))))) (. .))
(S (NP (JJ Categorical) (JJ logistic) (NN regression)) (VP (VBZ increases) (NP (DT the) (NN training) (NN accuracy)) (PP (IN from) (NP (QP (CD 72.30) (NN %) (IN to) (CD 81.40) (NN %)))) (PP (IN with) (NP (NP (DT a) (NN testing) (NN accuracy)) (PP (IN of) (NP (CD 63.46) (NN %)))))) (. .))
(S (NP (DT The) (NN study)) (ADVP (RB also)) (VP (VBZ shows) (SBAR (S (NP (NP (DT the) (JJ top) (CD 5) (NNS symptoms)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (RB mostly) (JJ likely)))))) (VP (VBZ indicates) (NP (NP (DT the) (NN presence)) (PP (IN in) (NP (NNP MM)))))))) (. .))
(S (NP (DT This) (NN study)) (VP (VBZ concludes) (SBAR (IN that) (S (S (VP (VBG using) (NP (JJ predictive) (NN modeling)))) (VP (MD can) (VP (VB enhance) (NP (NP (JJ primary) (NN presentation) (CC and) (NN diagnosis)) (PP (IN of) (NP (NNP MM))))))))) (. .))
